Spinogenix Announces Positive First Cohort Results from Phase 2a Trial Evaluating SPG302 for Alzheimer's Disease
SPG302, a Potential First-in-Class Synaptic Regenerative Therapy, Showed Progress in Cognitive Outcome Measures and a Favorable Safety Profile LOS ANGELES, Calif., Aug. 7, 2025 /PRNewswire/ -- Spin...
Could the data trigger insider trading activity, warrant exercises, or other capital‑structure events that traders should monitor?
How will the trial results affect the company’s cash runway and need for additional financing or equity raises?
What is the projected market size for a first‑in‑class synaptic regenerative therapy in Alzheimer’s disease and potential revenue upside?
17 days ago